Coherus Oncology, Inc. (CHRS) Stock Grade

About Coherus Oncology, Inc.'s fundamentals

Coherus Oncology is a small-cap biotechnology company with a market capitalization of $176.1 million that reported a significant net loss in its latest annual statement, resulting in a negative net margin of -403.8%. The company experienced severe revenue contraction, declining 84.2% year-over-year, indicating a substantial drop in sales. With no dividend yield and negative profitability metrics, the company is currently unprofitable and does not return capital to shareholders through dividends.